Breakthrough vaccine for the deadliest skin cancer cut risk by almost half

A Phase 3 trial of intismeran autogene, an mRNA cancer vaccine tailored to melanoma patients' tumor genetics, reduced the risk of recurrence or death by 42 percent, marking a promising advance in cancer treatment and prompting Moderna and Merck to engage regulatory authorities for approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 12 Oct 2026 and 24 Oct 2026.